GlobeNewsWire
12 Jun 2026, 09:36 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Novartis's Rhapsido (remibrutinib) met its primary endpoints in a global Phase III trial for chronic inducible urticaria (CIndU), becoming the first treatment to demonstrate efficacy in this area. — Successful Phase III results for a first-in-class therapy in an unmet medical need typically drive significant valuation increases for the drug's developer.
+0.60Novartis has submitted a supplemental New Drug Application (sNDA) to the FDA for the symptomatic dermographism (SD) subtype of CIndU. — Formal regulatory submission moves the drug closer to commercialization and revenue generation in the US market.
+0.40Rhapsido is already approved in the U.S., EU, China, and other markets for chronic spontaneous urticaria (CSU). — Existing approvals provide a baseline of safety and commercial infrastructure that lowers the risk profile for the new CIndU expansion.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Positive Phase III trial data for Rhapsido potentially making it the first targeted therapy for chronic inducible urticaria.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
9h ago
